Table of Contents
Advances in Geriatrics
Volume 2015 (2015), Article ID 270657, 6 pages
http://dx.doi.org/10.1155/2015/270657
Research Article

Testing Van Gool’s Hypothesis: A Method to Predict Side Effects of Cholinesterase Inhibitors in Patients with Cellular Degenerative and Vascular Dementia

1Department of Clinical Neuropsychology, VU University, 1081 BT Amsterdam, Netherlands
2Department of Geriatrics, Albert Schweitzer Hospital, 3318 AT Dordrecht, Netherlands
3Faculty of Social Sciences, Leiden University, 2300 RB Leiden, Netherlands
4Department of Psychiatry and Psychotherapy, Ludwig-Maximilian University, 80539 Munich, Germany
5Hersencentrum, 1016 XW Amsterdam, Netherlands

Received 9 November 2014; Revised 10 May 2015; Accepted 25 May 2015

Academic Editor: Stavros Baloyannis

Copyright © 2015 Liza van Eijk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients with Alzheimer’s disease (AD) and vascular dementia (VaD). Van Gool predicts that patients with cholinergic deficit symptoms will benefit from treatment whereas patients without will experience side effects because of overstimulation of the cholinergic system. We predicted that AD and VaD patients with a longer RT experience fewer side effects than patients with a faster response and that VaD patients have a longer RT than AD patients. A number of 71 patients with AD or VaD diagnosis were included. A sustained attention task was administered, as well as the MMSE and a questionnaire about side effects. Results indicated that VaD patients with a longer RT reported fewer side effects. Furthermore, patients with VaD had a longer RT than patients with AD. MMSE was negatively correlated with RT in the VaD group. Thus, the performance on the attention task seems associated with suffering from side effects and thus tends to predict medical outcome in VaD, but not in AD. Perhaps this attention task was not sensitive enough to measure cholinergic deficit symptoms in AD patients. Furthermore, different doses of medication might confound the effect for the AD group.